Metavia Inc. (MTVA) Stock Price & Analysis
Metavia Inc. (MTVA) fell 14.86% to USD 1.89 as of June 10, 2026 at 02:03 UTC, according to Nexqual real-time market data.
MTVA last closed at USD 2.22; the session ranged USD 1.7–1.95 on volume of 907,489 shares. Market capitalization is $9.76M, with a 52-week range of USD 0.97–19.03 (NCM). Source: Nexqual, June 10, 2026 at 02:03 UTC.
Key Statistics (as of June 10, 2026 at 02:03 UTC)
| Price | USD 1.89 |
|---|---|
| Change | ▼ 14.86% (down) |
| Previous Close | USD 2.22 |
| Open | USD 1.82 |
| Day Range | USD 1.7 – 1.95 |
| 52-Week Range | USD 0.97 – 19.03 |
| Volume | 907,489 shares |
| Market Cap | $9.76M |
| Exchange | NCM |
Technical Analysis (MTVA)
Nexqual's technical model rates MTVA "NEUTRAL" based on 3 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:03 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 44.06 (neutral) |
| vs SMA50 | Above (USD 1.76) |
| MACD | 0.2 (positive) |
Analyst Ratings (MTVA)
Wall Street analysts rate MTVA "Strong Buy" based on 3 analysts, with a mean price target of USD 19.33 (range USD 8–30), per Nexqual as of June 10, 2026 at 02:03 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 19.33 |
| High Target | USD 30 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (MTVA)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.79 vs est -0.76 ▼ miss |
| 2025-09-30 | USD -1.54 vs est -2.75 ▲ beat |
| 2025-06-30 | USD -2.86 vs est -2.46 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financials & Fundamentals (MTVA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -195.12% |
| Debt / Equity | 2.14 |
| Current Ratio | 2.73 |
| Total Cash | $13.73M |
| Total Debt | $194,000 |
| Free Cash Flow | $-10.40M |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Financial Health Score (MTVA)
Nexqual rates Metavia Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Critical — ROE -195%, ROA -65.3% |
Ownership (MTVA)
| Insider Ownership | +34.50% |
|---|---|
| Institutional Ownership | +13.38% |
| Shares Outstanding | 5.16M |
| Float | 3.39M |
| Short % of Float | +12.06% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
Leadership (MTVA)
Metavia Inc. is led by Hyung Heon Kim (age 48), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:03 UTC.
| CEO, President & Director | Hyung Heon Kim (age 48) |
|---|---|
| Chief Financial Officer | Marshall H. Woodworth (age 67) |
| Chief Scientific Officer | Mi-Kyung Kim |
| Senior Vice President of Clinical Operations | Robert Homolka |
| Senior Vice President of Business Development Advisor | Michael C. Pine (age 48) |
Major Backers & Investors (MTVA)
Notable institutional backers of Metavia Inc. include Fidelity, Jane Street Group, LLC, Aries Wealth Management, according to Nexqual as of June 10, 2026 at 02:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.64% |
| Jane Street Group, LLC | 0.21% |
| Aries Wealth Management | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.65% |
| Vanguard Group | 0.21% |
Source: Nexqual, June 10, 2026 at 02:03 UTC.
From Metavia Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
- Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
- The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIYA | Baiya International Group Inc. | USD 0.89 | ▲ 8.22% |
| MASK | 3 E Network Technology Group Lt | USD 3.01 | ▼ 21.31% |
| PCLA | PicoCELA Inc. | USD 6.5 | ▼ 8.45% |
| WOK | WORK Medical Technology Group L | USD 0.1 | ▲ 15.52% |
| PLRZ | Polyrizon Ltd. | USD 11.45 | ▼ 11.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:03 UTC. This page is informational and not investment advice.